Eli Lilly (NYSE:LLY) says the Food and Drug Administration approved its Trijardy XR tablet to help lower blood sugar in adults with type 2 diabetes.
Lilly says Trijardy combines three medicines –
Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin
hydrochloride extended release – in one pill, which will be a once-a-day
medication.
The FDA approval was based on two randomized
open-label trials that assessed the bioequivalence of empagliflozin,
linagliptin and metformin hydrochloride extended release fixed-dose
combination tablets and their individual components in healthy adults.
https://seekingalpha.com/news/3534972-fda-oks-trijardy-for-patients-type-2-diabetes-eli-lilly-says
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.